Immunovant, Inc.
IMVT$1.25B
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaDURHAM362 employees
Drugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Aug 10, 2026
7wMarket Overview
Stock performance and key metrics
IMVT News
Catalyst Timeline
4 upcoming, 1 past
Drug Pipeline
IMVT-1402
Chronic Inflammatory Demyelinating Polyneuropathy
Batoclimab
Thyroid Eye Disease
Batoclimab 680 mg SC weekly
Generalized Myasthenia Gravis
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
Chronic Inflammatory Demyelinating Polyneuropathy
RVT-1401
Myasthenia Gravis
IMVT-1401 (batoclimab)
Graves Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMVT-1402 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
Batoclimab | Phase 3 | Thyroid Eye Disease | - | - |
Batoclimab 680 mg SC weekly | Phase 3 | Generalized Myasthenia Gravis | - | - |
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
RVT-1401 | Phase 2 | Myasthenia Gravis | - | - |
IMVT-1401 (batoclimab) | Phase 2 | Graves Disease | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply